The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold: The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Trial
Open accessAbstract
Background— Many patients with implanted cardioverter defibrillators (ICDs) receive adjunctive antiarrhythmic drug therapy, most commonly amiodarone or sotalol. The effects of these drugs on defibrillation energy requirements have not been previously assessed in a randomized controlled trial. Methods and Results— The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) trial was a randomized clinical trial evaluating the efficacy of amiodarone plus β-blocker and sotalol versus β-blocker alone for reduction of ICD shocks. Within OPTIC, a prospectively designed substudy evaluated the effects of the 3 treatment arms on defibrillation energy requirements. Defibrillation thresholds (DFTs) were measured (binary step-down protocol) at baseline and again after 8 to 12 weeks of therapy in 94 patients, of whom 29 were randomized to receive β-blocker therapy (control group), 35 to amiodarone plus β-blocker, and 30 to sotalol. In the control group, the mean DFT decreased from 8.77±5.15 J at baseline to 7.13±3.43 J ( P =0.027); in the amiodarone group, DFT increased from 8.53±4.29 to 9.82±5.84 J ( P =0.091). In the sotalol group, DFT decreased from 8.09±4.81 to 7.20±5.30 J ( P =0.21). DFT changes in the β-blocker and the amiodarone group were significantly different ( P =0.006). In all patients, adequate safety margins for defibrillation were maintained. No clinical variable predicted baseline DFT or changes in DFT on therapy. Conclusion— Although amiodarone increased DFT, the effect size with modern ICD systems is very small. Therefore, DFT reassessment after the institution of antiarrhythmic drug therapy with amiodarone or sotalol is not routinely required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Data on the impact of antiarrhythmic drugs, used for atrial and ventricular arrhythmias, as well, on the defibrillation threshold are variable, but 1 randomized study 76 has suggested that amiodarone may increase, whereas sotalol and β-blockers decrease, the defibrillation threshold.”
From Managing with pacemakers and implantable cardioverter defibrillators (2013) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moss, A. J., Zaręba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Brown, M. W., & Andrews, M. L. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013474 · Cited by 6,885
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043399 · Cited by 6,552
Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy
Kadish, A. H., Dyer, A. R., Daubert, J. P., Quigg, R. J., Estes, N. A. M., Anderson, K. P., Calkins, H. G., Hoch, D., Goldberger, J. J., Shalaby, A. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033088 · Cited by 2,078
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials
Connolly, S. J. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2476 · Cited by 1,138
Self-citationConnolly, S. J. (2006) · JAMA · doi:10.1001/jama.295.2.165 · Cited by 788
Self-citationDesai, A. S., Fang, J. C., Maisel, W. H., & Baughman, K. L. (2004) · JAMA · doi:10.1001/jama.292.23.2874 · Cited by 403
Russo, A. M., Sauer, W. H., Gerstenfeld, E. P., Hsia, H. H., Lin, D., Cooper, J. M., Dixit, S., Verdino, R. J., Nayak, H. M., Callans, D. J., et al. (2005) · Heart Rhythm · doi:10.1016/j.hrthm.2005.01.015 · Cited by 191
Epstein, A. E., Ellenbogen, K. A., Kirk, K. A., Kay, G. N., Dailey, S. M., & Plumb, V. J. (1992) · Circulation · doi:10.1161/01.cir.86.4.1206 · Cited by 174
Effects of chronic amiodarone therapy on defibrillation threshold
Jung, W., MANZ, M., Pizzulli, L., Pfeiffer, D., & Lüderitz, B. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90354-2 · Cited by 138
Efficacy and Temporal Stability of Reduced Safety Margins for Ventricular Defibrillation
Gold, M. R., Higgins, S. L., Klein, R. C., Gilliam, F. R., Kopelman, H. A., Hessen, S. E., PAYNE, J. P., Strickberger, S. A., Breiter, D. J., & Hahn, S. J. (2002) · Circulation · doi:10.1161/01.cir.0000015508.59749.f5 · Cited by 136
Cited by
Sorted by citations
Priori, S. G., Blomström-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., Elliott, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv316 · Cited by 3,893
Authors Task Force Members, Priori, S. G., Blomström‐Lundqvist, C., Mazzanti, A., Blom, N. A., Borggrefe, M., Camm, J. A., Elliot, P. M., Fitzsimons, D., Hatala, R., et al. (2015) · EP Europace · doi:10.1093/europace/euv319 · Cited by 1,671
Vassallo, P., & Trohman, R. G. (2007) · JAMA · doi:10.1001/jama.298.11.1312 · Cited by 449
Healey, J. S., Hohnloser, S. H., Glikson, M., Neuzner, J., Mabo, P., Viñolas, X., Kautzner, J., O’Hara, G. E., VanErven, L., Gadler, F., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61903-6 · Cited by 244
Self-citationDan, G., Martínez‐Rubio, A., Agewall, S., Boriani, G., Borggrefe, M., Gaïta, F., Gelder, I. C. V., Görenek, B., Kaski, J. C., Kjeldsen, K. P., et al. (2018) · EP Europace · doi:10.1093/europace/eux373 · Cited by 247
Metadata
- Authors
- Hohnloser, S. H., Dorian, P., Roberts, R., Gent, M., Israel, C. W., Fain, E., Champagne, J., & Connolly, S. J.
- Affiliations
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- Circulation
- Published
- 2006-07-11
- Volume
- 114
- Issue
- 2
- Pages
- 104-109
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2026225505
- Cited by
- 179
- References
- 31
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 9 · 2017: 11 · 2016: 6 · 2015: 10 · 2014: 6 · 2013: 10 · 2012: 19
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- McMaster University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Keywords
- amiodarone, sotalol, implantable cardioverter-defibrillator, antiarrhythmic drugs, beta-blockers, defibrillation energy requirements, ICD shocks
- MeSH terms
- Carvedilol, Adrenergic beta-Antagonists, Aged, Amiodarone, Anti-Arrhythmia Agents, Atrial Fibrillation, Carbazoles, Combined Modality Therapy, Female, Heart Arrest, Humans, Male, Metoprolol, Middle Aged, Myocardial Infarction, Propanolamines, Sotalol, Ventricular Fibrillation, Ventricular Function, Left, Defibrillators, Implantable, Bisoprolol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
